EUR 4.23
(0.95%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 20.64 Million EUR | 19.05% |
2022 | 17.34 Million EUR | -29.18% |
2021 | 24.48 Million EUR | 85.44% |
2020 | 13.2 Million EUR | 32.92% |
2019 | 9.93 Million EUR | 34.9% |
2018 | 7.36 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 6.13 Million EUR | 28.88% |
2024 Q2 | 6.13 Million EUR | 0.0% |
2023 Q1 | 5.55 Million EUR | -68.62% |
2023 FY | 35.26 Million EUR | 103.39% |
2023 Q4 | 4.76 Million EUR | -9.46% |
2023 Q3 | 5.26 Million EUR | -72.86% |
2023 Q2 | 19.37 Million EUR | 248.54% |
2022 Q1 | 4.58 Million EUR | -25.45% |
2022 Q3 | 5.19 Million EUR | -66.99% |
2022 Q4 | 17.71 Million EUR | 241.3% |
2022 Q2 | 15.72 Million EUR | 243.17% |
2022 FY | 17.34 Million EUR | -29.18% |
2021 Q1 | 2.88 Million EUR | 12.29% |
2021 FY | 24.48 Million EUR | 85.44% |
2021 Q4 | 6.14 Million EUR | 0.0% |
2021 Q3 | 6.14 Million EUR | 112.87% |
2021 Q2 | 2.88 Million EUR | 0.0% |
2020 Q2 | 1.54 Million EUR | 0.0% |
2020 Q3 | 2.57 Million EUR | 66.44% |
2020 Q1 | 1.54 Million EUR | 0.0% |
2020 FY | 13.2 Million EUR | 32.92% |
2020 Q4 | 2.57 Million EUR | 0.0% |
2019 FY | 9.93 Million EUR | 34.9% |
2018 FY | 7.36 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Nicox S.A. | -11.5 Million EUR | 279.475% |
European Medical Solutions | 13.64 Million EUR | -51.279% |
FERMENTALG | 12.34 Million EUR | -67.247% |
argenx SE | 1.34 Billion EUR | 98.462% |
BioSenic S.A. | 7.58 Million EUR | -172.254% |
Celyad Oncology SA | 8.49 Million EUR | -143.168% |
Hyloris Pharmaceuticals SA | 17.98 Million EUR | -14.777% |
Oxurion NV | 12.21 Million EUR | -69.027% |
PHAXIAM Therapeutics S.A. | 24.98 Million EUR | 17.374% |
Financière de Tubize SA | 114.38 Thousand EUR | -17948.064% |
UCB SA | 2.94 Billion EUR | 99.298% |